Zelboraf

Zelboraf is a brand name of vemurafenib, approved by the FDA in the following formulation(s):

ZELBORAF (vemurafenib - tablet; oral)

• 
  Manufacturer: HOFFMANN LA ROCHE
  
  Approval date: August 17, 2011
  
  Strength(s): 240MG ^[RLD]

Has a generic version of Zelboraf been approved?

No. There is currently no therapeutically equivalent version of Zelboraf available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zelboraf. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compounds and methods for development of Ret modulators
  Patent 7,504,509
  Issued: March 17, 2009
  Inventor(s): Ibrahim; Prabha & Artis; Dean Richard & Bremer; Ryan & Habets; Gaston & Hurt; Clarence R. & Mamo; Shumeye & Nespi; Marika & Zhang; Chao & Zhang; Jiazhong & Zhu; Yong & Zuckerman; Rebecca & Krupka; Heike & Kumar; Abhinav & West; Brian
  Assignee(s): Plexxikon, Inc.
  Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.
  
  Patent expiration dates:
  
  
  • October 22, 2026
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Compounds and methods for kinase modulation, and indications therefor
  Patent 7,863,288
  Issued: January 4, 2011
  Inventor(s): Ibrahim; Prabha N. & Artis; Dean R. & Bremer; Ryan & Mamo; Shumeye & Zhang; Chao & Zhang; Jiazhong & Tsai; James & Hirth; Klaus-Peter & Bollag; Gideon & Spevak; Wayne & Cho; Hanna & Gillette; Samuel J. & Shi; Shenghua
  Assignee(s): Plexxikon, Inc.
  Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
  
  Patent expiration dates:
  
  
  • June 20, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 17, 2016 - NEW CHEMICAL ENTITY
  
  
  • August 17, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Zelboraf Consumer Information (Drugs.com)
• Zelboraf Consumer Information (Wolters Kluwer)
• Zelboraf Consumer Information (Cerner Multum)
• Vemurafenib Consumer Information (Wolters Kluwer)
• Vemurafenib Consumer Information (Cerner Multum)